These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Study assigns dollar value to alteplase-streptokinase debate. Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819 [No Abstract] [Full Text] [Related]
4. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799 [TBL] [Abstract][Full Text] [Related]
5. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Califf RM; Stump D; Topol EJ; Mark DB Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606 [No Abstract] [Full Text] [Related]
6. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Woo KS; White HD Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049 [TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective]. Lorenzoni R; Fattore G; Gensini G G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862 [TBL] [Abstract][Full Text] [Related]
9. Is alteplase (t-PA) more cost-effective than streptokinase? Sanchez LA Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065 [No Abstract] [Full Text] [Related]
10. Emergent decision-making: defining the patient perspective. Knudtson ML Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261 [No Abstract] [Full Text] [Related]
13. Thrombolytic therapy for acute myocardial infarction. Clem JR S D J Med; 1994 Jan; 47(1):27-8. PubMed ID: 8122094 [No Abstract] [Full Text] [Related]
14. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy. Lessler DS; Avins AL Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400 [TBL] [Abstract][Full Text] [Related]
15. Thrombolytic therapy with alteplase for ischaemic stroke. Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701 [TBL] [Abstract][Full Text] [Related]
16. Who uses streptokinase vs alteplase (t-PA), and why? Sanchez LA Pharmacoeconomics; 1992 Nov; 2(5):428-9. PubMed ID: 10172066 [No Abstract] [Full Text] [Related]
17. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K; Ellis CJ; White HD Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173 [TBL] [Abstract][Full Text] [Related]
18. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs. Tsui W; Pierre K; Massel D Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260 [TBL] [Abstract][Full Text] [Related]
19. Evaluation and comparison of the adverse effects of streptokinase and alteplase. Tisdale JE; Colucci RD; Ujhelyi MR; Kluger J; Fieldman A; Chow MS Pharmacotherapy; 1992; 12(6):440-4. PubMed ID: 1492007 [TBL] [Abstract][Full Text] [Related]
20. Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice? Weber JJ; Chong K Am J Health Syst Pharm; 1998 Nov; 55(22):2414-6. PubMed ID: 9825039 [No Abstract] [Full Text] [Related] [Next] [New Search]